Linked Life Data

20460520

Source:http://linkedlifedata.com/resource/pubmed/id/20460520

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2010-5-14
pubmed:abstractText
LIGHT, a ligand for the lymphotoxin-beta receptor, establishes lymphoid-like tissues inside tumor sites and recruits naïve T cells into the tumor. However, whether these infiltrating T cells are specific for tumor antigens is not known. We hypothesized that therapy with LIGHT can expand functional tumor-specific CD8(+) T cells that can be boosted using HPV16E6E7-Venezuelan equine encephalitis virus replicon particles (HPV16-VRP) and that this combined therapy can eradicate human papillomavirus 16 (HPV16)-induced tumors. Our data show that forced expression of LIGHT in tumors results in an increase in expression of IFNgamma and chemoattractant cytokines such as interleukin-1a, MIG, and macrophage inflammatory protein-2 within the tumor and that this tumor microenvironment correlates with an increase in frequency of tumor-infiltrating CD8(+) T cells. Forced expression of LIGHT also results in the expansion of functional T cells that recognize multiple tumor antigens, including HPV16 E7, and these T cells prevent the outgrowth of tumors on secondary challenge. Subsequent boosting of E7-specific T cells by vaccination with HPV16-VRP significantly increases their frequency in both the periphery and the tumor and leads to the eradication of large well-established tumors, for which either treatment alone is not successful. These data establish the safety of Ad-LIGHT as a therapeutic intervention in preclinical studies and suggest that patients with HPV16(+) tumors may benefit from combined immunotherapy with LIGHT and antigen-specific vaccination.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10358764, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10462249, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10493167, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10508626, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10590126, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10617422, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10700230, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10779757, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10799510, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-10924796, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-11691804, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-11926408, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-12115617, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-12740040, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-12974479, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-14670335, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-15771586, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-17283172, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-17641063, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-17973257, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-18245488, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-19128255, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-3960438, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-7589138, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-7690326, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-9434729, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-9462508, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-9679975, http://linkedlifedata.com/resource/pubmed/commentcorrection/20460520-9813200
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1538-7445
pubmed:author
pubmed:copyrightInfo
(c)2010 AACR.
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3955-64
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed-meshheading:20460520-Animals, pubmed-meshheading:20460520-CD8-Positive T-Lymphocytes, pubmed-meshheading:20460520-Cancer Vaccines, pubmed-meshheading:20460520-Combined Modality Therapy, pubmed-meshheading:20460520-Encephalitis Virus, Venezuelan Equine, pubmed-meshheading:20460520-Female, pubmed-meshheading:20460520-Flow Cytometry, pubmed-meshheading:20460520-Human papillomavirus 16, pubmed-meshheading:20460520-Humans, pubmed-meshheading:20460520-Interferon-gamma, pubmed-meshheading:20460520-Lymphocytes, Tumor-Infiltrating, pubmed-meshheading:20460520-Mice, pubmed-meshheading:20460520-Mice, Inbred C57BL, pubmed-meshheading:20460520-Neoplasms, Experimental, pubmed-meshheading:20460520-Papillomavirus E7 Proteins, pubmed-meshheading:20460520-Papillomavirus Infections, pubmed-meshheading:20460520-Peptide Fragments, pubmed-meshheading:20460520-Replicon, pubmed-meshheading:20460520-Survival Rate, pubmed-meshheading:20460520-Tumor Necrosis Factor Ligand Superfamily Member 14, pubmed-meshheading:20460520-Vaccination
pubmed:year
2010
pubmed:articleTitle
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.
pubmed:affiliation
Department of Molecular Microbiology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't
More...